Black Entrepreneur and Scientist Dr. Isa Odidi to Ring The NASDAQ Stock Market Opening Bell

Dr. Isa Odidi, Chief Executive Officer of Intellipharmaceutics International Inc. (IPCI), will ring the NASDAQ Opening Bell on Friday, October 22, 2010.

In the pharmaceutical industry, Dr. Odidi is highly regarded for his entrepreneurial acumen, something rare for a scientist. Dr. Odidi is also a highly respected innovator and inventor with a long history of success. His work has been cited in textbooks and he has published over a hundred scientific and medical papers, articles and textbooks.

About Intellipharmaceutics International Inc. (IPCI):

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel or generic controlled release and targeted release oral solid dosage drugs. The Company's patented Hypermatrix(tm) technology is a unique and validated multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology, Intellipharmaceutics has a pipeline of products in various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, pain and infection. The Company has three products under review with the FDA for the purpose of obtaining regulatory approval.

Intellipharmaceutics' lead generic product under development is Dexmethylphenidate XR (dexmethylphenidate hydrochloride), a generic version of Focalin XR(R), which is an extended-release capsule for the treatment of Attention Deficit Hyperactivity Disorder. In 2008, Focalin(R), including Focalin XR(R), had U.S. sales of approximately U.S. $350 million. Intellipharmaceutics' generic products under review with the FDA also include generic versions of Protonix DR and Effexor XR.

Intellipharmaceutics' lead non-generic product under development is Rexista(TM) oxycodone, an abuse- and alcohol-deterrent controlled-release oral formulation of controlled-release oxycodone hydrochloride for the relief of pain. Rexista(TM) oxycodone is a unique dosage form designed to be deterrent to some of the well-documented abuses associated with currently marketed oxycodone products, such as abuse of these drugs by nasal inhalation when crushed or powdered and by injection when combined with solvents. Rexista(TM) oxycodone is also designed to resist release of the entire dose when consumed with alcohol, a significant problem with some opioid drugs. In 2008, oxycodone had U.S. sales of approximately U.S. $2 billion.